We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Ridgeback Biotherapeutics announced the implementation of an expanded access protocol to ensure rapid access to its Ebola treatment, ansuvimab, in the Democratic Republic of the Congo (DRC).